2025
Surgical Management of Breast Cancer Liver Metastasis
Rahnemai-Azar A, Selby L, Lustberg M, Pawlik T. Surgical Management of Breast Cancer Liver Metastasis. Hematology/Oncology Clinics Of North America 2025, 39: 25-35. PMID: 39510675, DOI: 10.1016/j.hoc.2024.08.012.Peer-Reviewed Original ResearchConceptsBreast cancer liver metastasesSystemic chemotherapyHepatic resectionAblation therapyIsolated breast cancer liver metastasesLong-term outcomes of womenProlonged disease-free intervalLocal-regional therapyCancer liver metastasesDisease-free intervalOutcomes of womenBreast cancer metastasisLong-term outcomesRegional therapyLiver metastasesOverall survivalSurgery benefitMultidisciplinary settingCancer metastasisPatientsResectionChemotherapyMetastasisTherapySurgery
2024
Predictors of Post-Hepatectomy Liver Failure in Klatskin Tumors: The Role of Preoperative Glucose, Future Liver Remnant to Spleen Ratio, and Early Bilirubin Monitoring
Kim S, Ku H, Moon H, Song S, Choi Y, Shin D, Koh Y, Oh N, Rhu J, Lee G, Yang W, Song J, Kang C, Ku S, Choi A. Predictors of Post-Hepatectomy Liver Failure in Klatskin Tumors: The Role of Preoperative Glucose, Future Liver Remnant to Spleen Ratio, and Early Bilirubin Monitoring. Diagnostics 2024, 14: 2716. PMID: 39682624, PMCID: PMC11640423, DOI: 10.3390/diagnostics14232716.Peer-Reviewed Original ResearchPost-hepatectomy liver failurePredictors of post-hepatectomy liver failureKlatskin tumorReceiver Operating CharacteristicPreoperative glucoseLiver failurePredicting post-hepatectomy liver failureSpleen ratioChonnam National University Hwasun HospitalRisk of post-hepatectomy liver failureKosin University Gospel HospitalPreoperative glucose controlPreoperative glucose levelsFuture liver remnantAffecting patient prognosisReceiver operating characteristic analysisMonitoring of TBEarly postoperative monitoringHepatic resectionHemi-hepatectomyPostoperative predictorsRetrospective reviewLiver remnantSpleen volumeExtrahepatic cholangiocarcinomavon Meyenburg complexes are more frequently associated with cholangiocarcinoma
Jain D, Khandakar B, Ni P, Kenney B, Qin L, Deshpande V, Fiel M. von Meyenburg complexes are more frequently associated with cholangiocarcinoma. Journal Of Clinical Pathology 2024, 78: 300-306. PMID: 38729770, DOI: 10.1136/jcp-2024-209572.Peer-Reviewed Original ResearchVon Meyenburg complexesHilar CCHepatic resectionCC casesChronic viral hepatitis BAssociated liver disordersMeyenburg complexesProgress to cholangiocarcinomaDysplasia/carcinoma in situMetastatic colon carcinomaViral hepatitis BCases of CCBile duct adenomaPolycystic kidney diseaseAssociated with cholangiocarcinomaBenign lesionsCryptogenic cirrhosisHepatitis BBiliary diseaseColon carcinomaMiscellaneous disordersKidney diseaseLiver diseaseCholangiocarcinomaLiver disorders
2022
Hepatectomy is associated with improved oncologic outcomes in recurrent colorectal liver metastases: A propensity-matched analysis
Sutton T, Wong L, Walker B, Dewey E, Eil R, Lopez C, Kardosh A, Chen E, Rocha F, Billingsley K, Mayo S. Hepatectomy is associated with improved oncologic outcomes in recurrent colorectal liver metastases: A propensity-matched analysis. Surgery 2022, 173: 1314-1321. PMID: 36435651, DOI: 10.1016/j.surg.2022.10.019.Peer-Reviewed Original ResearchConceptsColorectal liver metastasesPost-recurrence overall survivalRepeat hepatic resectionRecurrent colorectal liver metastasesHepatic resectionLiver metastasesSystemic treatmentOverall survivalIntrahepatic recurrenceOncologic outcomesSystemic therapyMedian post-recurrence overall survivalRetrospective single-institution cohort studySingle-institution cohort studyCurative-intent hepatectomyImproved oncologic outcomesPerioperative systemic therapyRelevant clinicopathologic variablesSignificant clinicopathologic differencesPropensity-matched analysisRole of resectionCox proportional hazardsLiver recurrencePerioperative chemotherapyCohort study
2020
Surgical Management of Breast Cancer Liver Metastasis
Rahnemai-Azar AA, Selby LV, Lustberg MB, Pawlik TM. Surgical Management of Breast Cancer Liver Metastasis. Surgical Oncology Clinics Of North America 2020, 30: 27-37. PMID: 33220807, DOI: 10.1016/j.soc.2020.09.003.Peer-Reviewed Original ResearchConceptsBreast cancer liver metastasesCancer liver metastasesSystemic chemotherapyHepatic resectionLiver metastasesAblative therapyProlonged disease-free intervalDisease-free intervalBetter overall survivalLong-term outcomesLocal-regional therapyEffective systemic chemotherapyBreast cancer metastasisLimited diseaseOverall survivalRegional therapySurgical managementSurgery benefitMultidisciplinary settingPatientsCancer metastasisMetastasisTherapyResectionChemotherapy
2019
Hepatic resection of solitary HCC in the elderly: A unique disease in a growing population
Zarour LR, Billingsley KG, Walker BS, Enestvedt CK, Orloff SL, Maynard E, Mayo SC. Hepatic resection of solitary HCC in the elderly: A unique disease in a growing population. The American Journal Of Surgery 2019, 217: 899-905. PMID: 30819401, DOI: 10.1016/j.amjsurg.2019.01.030.Peer-Reviewed Original ResearchConceptsSolitary hepatocellular carcinomaPrognostic nutritional indexHepatic resectionElderly patientsUnique diseaseLow prognostic nutritional indexMedian Child-Pugh scoreTumor size 5Child-Pugh scoreGrade III complicationsHalf of patientsRecurrence-free survivalSolitary HCCExtrahepatic recurrenceProspective databaseR0 resectionIntrahepatic recurrenceMajor hepatectomyMedian survivalOverall survivalViral hepatitisLow morbidityMedian ageClinicopathologic dataClinicopathologic differences
2017
Preoperative optimization for major hepatic resection
Walcott-Sapp S, Billingsley KG. Preoperative optimization for major hepatic resection. Langenbeck's Archives Of Surgery 2017, 403: 23-35. PMID: 29150719, DOI: 10.1007/s00423-017-1638-x.Peer-Reviewed Original ResearchConceptsMajor hepatic resectionHepatic resectionExercise capacityLiver diseaseMajor liver resectionUnderlying liver diseaseChronic liver diseasePrimary hepatobiliary malignanciesPathophysiology of changesPreoperative preparation programHepatectomy patientsPreoperative optimizationExercise toleranceMajor hepatectomyPostoperative complicationsLiver resectionMetastatic diseasePostoperative outcomesHepatobiliary malignanciesPreoperative evaluationExercise programExercise trainingFatty infiltrationHepatic steatosisMuscle strengthUpdate on Embolization Therapies for Hepatocellular Carcinoma
Kishore S, Friedman T, Madoff DC. Update on Embolization Therapies for Hepatocellular Carcinoma. Current Oncology Reports 2017, 19: 40. PMID: 28421483, DOI: 10.1007/s11912-017-0597-2.Peer-Reviewed Original ResearchConceptsEmbolization therapyHepatocellular carcinomaFuture liver remnant hypertrophyPortal vein tumor thrombusPlanned hepatic resectionStage C diseaseBCLC stage AEarly-stage patientsManagement of patientsSafety of resectionVein tumor thrombusRadiation lobectomyRadiation segmentectomyUnresectable HCCUnifocal diseaseHepatic resectionVein embolizationBCLC stageStage patientsSurvival benefitTumor thrombusAblative optionsB diseaseC diseaseDifferent therapies
2016
Aggressive approach to hepatic resection and adjuvant tyrosine kinase inhibitor therapy for metastatic gastrointestinal stroma tumors: Outcomes on survival
Pichardo E, Castillo A, Heinrich M, Billingsley K. Aggressive approach to hepatic resection and adjuvant tyrosine kinase inhibitor therapy for metastatic gastrointestinal stroma tumors: Outcomes on survival. Hepato Pancreato Biliary 2016, 18: e171. DOI: 10.1016/j.hpb.2016.02.408.Peer-Reviewed Original ResearchControversies of preoperative portal vein embolization
May BJ, Madoff DC. Controversies of preoperative portal vein embolization. Hepatic Oncology 2016, 3: 155-166. PMID: 30191035, PMCID: PMC6095422, DOI: 10.2217/hep-2015-0004.Peer-Reviewed Original ResearchPortal Venous Interventions: State of the Art
Madoff DC, Gaba RC, Weber CN, Clark TW, Saad WE. Portal Venous Interventions: State of the Art. Radiology 2016, 278: 333-353. PMID: 26789601, DOI: 10.1148/radiol.2015141858.Peer-Reviewed Original ResearchConceptsBalloon retrograde transvenous obliterationEnd-stage liver diseaseIntrahepatic portosystemic shunt placementPreoperative portal vein embolizationTransjugular intrahepatic portosystemic shunt placementPortal venous interventionsMajor hepatic resectionPortal vein embolizationPortosystemic shunt placementPortal venous systemRetrograde transvenous obliterationIslet cell transplantationHepatic resectionVein embolizationDiabetes mellitusVenous interventionsLiver diseaseShunt placementClinical manifestationsTransvenous obliterationCell transplantationVenous systemUntoward effectsLiver cancerCellular therapy
2014
Hepatectomy for hemangioma; safe, but is it successful?
Groeschl R, Riggle K, Quebbeman E, Christians K, Turaga K, Tsai S, Gamblin T. Hepatectomy for hemangioma; safe, but is it successful? Hepatogastroenterology 2014, 61: 2009-13. PMID: 25713903.Peer-Reviewed Original ResearchConceptsLiver resectionHepatic hemangiomaAbdominal discomfortEffect of liver resectionMedian Follow-UpMedian lesion sizeHepatic hemangiomataHPB centersHepatic resectionPreoperative painConsecutive patientsPerioperative deathsHepatobiliary surgeonsMedian agePain reliefSignificant morbidityEvaluating patientsTreat such symptomsHemangioma resectionResectionFollow-upHemangiomaLesion sizePatientsPainA comparison of open and minimally invasive surgery for hepatic and pancreatic resections using the nationwide inpatient sample
Ejaz A, Sachs T, He J, Spolverato G, Hirose K, Ahuja N, Wolfgang CL, Makary MA, Weiss M, Pawlik TM. A comparison of open and minimally invasive surgery for hepatic and pancreatic resections using the nationwide inpatient sample. Surgery 2014, 156: 538-547. PMID: 25017135, PMCID: PMC4316739, DOI: 10.1016/j.surg.2014.03.046.Peer-Reviewed Original ResearchConceptsMIS patientsInpatient outcomesLiver operationsNationwide Inpatient Sample databasePreoperative medical comorbiditiesIncidence of complicationsMultiple comorbid conditionsShorter median lengthAppropriate International ClassificationNationwide Inpatient SampleInvasive surgery techniquesDuration of stayHospital mortalityPostoperative morbidityHepatic resectionMedical comorbiditiesPancreatic resectionComorbid conditionsMIS groupMedian lengthOpen surgeryInpatient SampleOpen procedureRobotic assistInternational ClassificationSystematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease
Hwang M, Jayakrishnan T, Green D, George B, Thomas J, Groeschl R, Erickson B, Pappas S, Gamblin T, Turaga K. Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. European Journal Of Cancer 2014, 50: 1747-1757. PMID: 24767470, DOI: 10.1016/j.ejca.2014.03.277.Peer-Reviewed Original ResearchConceptsColorectal liver metastasesExtra-hepatic diseaseMedian survivalOverall survivalHepatic resectionLiver metastasesHepatic diseaseColorectal liver metastases patientsDistribution of metastatic diseaseOperative mortality rateSignificant survival benefitMinimal liver diseaseOutcomes of patientsPrimary outcome measureMetastatic diseaseSurgical resectionMultimodal therapySurvival benefitLymph nodesResectionLiver diseasePatientsPrimary exposureMeta-regression techniquesMortality ratePrognosis of Patients With Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
Njei B, Konjeti VR, Ditah I. Prognosis of Patients With Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Gastrointestinal Cancer Research : GCR 2014, 7: 49-54. PMID: 24799971, PMCID: PMC4007676.Peer-Reviewed Original ResearchMean overall survivalOverall survivalFL-HCCHepatocellular carcinomaNoncirrhotic patientsSystematic reviewConventional HCCPrognosis of patientsConventional hepatocellular carcinomaFibrolamellar hepatocellular carcinomaRandom-effects modelOutcomes of interestSignificant increaseTypes of HCCLiver transplantationFibrolamellar variantHepatic resectionBetter prognosisClinical courseSurvival outcomesTherapeutic optionsCochrane LibrarySubgroup analysisEgger's testRevMan 5.1
2013
Anatomic Considerations in the Surgical Resection of Hepatocellular Carcinoma
Yoo PS, Enestvedt CK, Kulkarni S. Anatomic Considerations in the Surgical Resection of Hepatocellular Carcinoma. Journal Of Clinical Gastroenterology 2013, 47: s11-s15. PMID: 23632343, DOI: 10.1097/mcg.0b013e318280ce5f.Peer-Reviewed Original ResearchConceptsOrthotopic liver transplantationSurgical resectionHepatocellular carcinomaNonanatomic resectionLiver transplantationTreatment of HCCFormal anatomic resectionInferior oncologic outcomesResidual liver massExtent of resectionCommon primary malignancyFunctional hepatic parenchymaRelevant surgical anatomyLocoregional therapySystemic chemotherapyAnatomic resectionHepatic resectionOncologic outcomesPrimary malignancyCancer deathHepatic parenchymaSurgical techniqueCommon causeAdvanced casesResectionUpdate on Portal Vein Embolization: Evidence-based Outcomes, Controversies, and Novel Strategies
May BJ, Talenfeld AD, Madoff DC. Update on Portal Vein Embolization: Evidence-based Outcomes, Controversies, and Novel Strategies. Journal Of Vascular And Interventional Radiology 2013, 24: 241-254. PMID: 23369559, DOI: 10.1016/j.jvir.2012.10.017.Peer-Reviewed Original ResearchConceptsPortal vein embolizationFuture liver remnantVein embolizationCurative hepatic resectionPortal blood flowNumber of patientsTumor-bearing liverRecent outcome dataEvidence-based outcomesPostoperative morbidityFLR hypertrophyHepatic resectionLiver remnantPatient outcomesBlood flowOutcome dataNovel strategyEmbolizationSurgeryTherapyOutcomesMorbidityResectionPatientsHypertrophy
2012
Hepatic Hemangiopericytoma/Solitary Fibrous Tumor: A Review of Our Current Understanding and Case Study
Bokshan SL, Doyle M, Becker N, Nalbantoglu I, Chapman WC. Hepatic Hemangiopericytoma/Solitary Fibrous Tumor: A Review of Our Current Understanding and Case Study. Journal Of Gastrointestinal Surgery 2012, 16: 2170-2176. PMID: 22854953, DOI: 10.1007/s11605-012-1947-x.Peer-Reviewed Case Reports and Technical NotesConceptsSolitary fibrous tumorProlonged steroid useSoft tissue tumorsSoft tissue neoplasmWorld Health OrganizationAdjuvant radiotherapyHepatic resectionInoperable casesSteroid useIGF-IICurrent mainstayPainless massMost lesionsVascular neoplasmFibrous tumorMarked hypoglycemiaTissue tumorsDiagnostic modalitiesHemangiopericytomaChemotherapeutic approachesMesenchymal originNeoplasmsHealth OrganizationAntiangiogenic compoundsTumorsPortal Vein Embolization: Rationale, Technique, and Current Application
May B, Madoff D. Portal Vein Embolization: Rationale, Technique, and Current Application. Seminars In Interventional Radiology 2012, 29: 081-089. PMID: 23729977, PMCID: PMC3444878, DOI: 10.1055/s-0032-1312568.Peer-Reviewed Original ResearchPortal vein embolizationFuture liver remnantPreoperative portal vein embolizationCurative-intent resectionComplicated postoperative courseNumber of patientsPostoperative morbidityHepatic resectionPostoperative courseVein embolizationSurgical outcomesLiver remnantPortal bloodLiver segmentsResectionTherapyCurrent useTechnical considerationsEmbolizationMorbidityPatientsSurgeryHypertrophyBlood
2011
Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance
D'Angelica M, Ammori J, Gonen M, Klimstra D, Low P, Murphy L, Weiser M, Paty P, Fong Y, DeMatteo R, Allen P, Jarnagin W, Shia J. Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance. Modern Pathology 2011, 24: 1221-1228. PMID: 21572402, DOI: 10.1038/modpathol.2011.82.Peer-Reviewed Original ResearchConceptsClinical risk scoreHepatic colorectal cancer metastasesFRA expressionColorectal cancer metastasesAssociated with outcomePrognostic valueRisk scoreStage IV colorectal cancer patientsCancer metastasisEarly death groupResectable liver metastasesFolate receptor 1Year of surgeryFolate receptor alphaClinical risk factorsGroup of patientsAssociated with survivalColorectal cancer patientsPotential biological differencesHepatic resectionLiver metastasesLiver resectionClinical predictorsTissue microarrayPotential therapeutic target
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply